AAPL342.94-0.52 (-0.15%) ▼|ABBV282.68-2.74 (-0.96%) ▼|ABT104.06-0.83 (-0.79%) ▼|ACN236.93+7.25 (+3.16%) ▲|ADBE247.09+1.89 (+0.77%) ▲|AMAT413.11+3.82 (+0.93%) ▲|AMD538.05+9.30 (+1.76%) ▲|AMGN424.94-7.55 (-1.75%) ▼|AMT183.03-2.24 (-1.21%) ▼|AMZN262.45+12.45 (+4.98%) ▲|AVGO334.59+5.84 (+1.78%) ▲|AXP316.41+2.82 (+0.90%) ▲|BA191.42+1.21 (+0.64%) ▲|BAC50.39-0.84 (-1.64%) ▼|BKNG162.60-0.85 (-0.52%) ▼|BLK1,124.60-9.78 (-0.86%) ▼|BMY58.83-0.92 (-1.54%) ▼|BNY142.44-0.86 (-0.60%) ▼|BRK-B532.23+0.21 (+0.04%) ▲|C121.69-2.57 (-2.07%) ▼|CAT725.79-4.97 (-0.68%) ▼|CL93.39-0.72 (-0.77%) ▼|CMCSA21.90+0.00 (+0.00%) ▲|COF199.83-1.91 (-0.95%) ▼|COP145.24-1.27 (-0.87%) ▼|COST995.53+6.42 (+0.65%) ▲|CRM242.45+1.75 (+0.73%) ▲|CSCO106.50-0.89 (-0.83%) ▼|CVS92.68+0.32 (+0.35%) ▲|CVX224.37-0.62 (-0.28%) ▼|DE627.00-14.86 (-2.32%) ▼|DHR224.43-4.61 (-2.01%) ▼|DIS109.59-1.00 (-0.90%) ▼|DUK119.27-2.20 (-1.81%) ▼|EMR160.54-0.93 (-0.58%) ▼|FDX293.78+0.23 (+0.08%) ▲|GD341.43-2.80 (-0.81%) ▼|GE311.28-2.55 (-0.81%) ▼|GEV908.44-12.76 (-1.39%) ▼|GILD153.07-3.12 (-2.00%) ▼|GM82.75-1.21 (-1.44%) ▼|GOOG340.16+3.25 (+0.96%) ▲|GOOGL344.18+3.59 (+1.05%) ▲|GS875.78-5.48 (-0.62%) ▼|HD309.88+0.25 (+0.08%) ▲|HON209.98-1.43 (-0.68%) ▼|IBM236.39+4.25 (+1.83%) ▲|INTC92.03+2.18 (+2.43%) ▲|INTU325.62+0.47 (+0.14%) ▲|ISRG433.18+6.48 (+1.52%) ▲|JNJ253.79-1.77 (-0.69%) ▼|JPM333.53-6.19 (-1.82%) ▼|KO93.42-0.48 (-0.51%) ▼|LIN503.44+5.01 (+1.01%) ▲|LLY1,240.34-16.69 (-1.33%) ▼|LMT548.23-3.86 (-0.70%) ▼|LOW195.92-1.46 (-0.74%) ▼|LRCX272.20+8.26 (+3.13%) ▲|MA616.40-1.02 (-0.17%) ▼|MCD242.67-0.30 (-0.12%) ▼|MDLZ63.34-0.57 (-0.89%) ▼|MDT92.77-1.98 (-2.09%) ▼|META705.44-3.89 (-0.55%) ▼|MMM162.01-2.74 (-1.66%) ▼|MO74.09-1.02 (-1.36%) ▼|MRK143.63-2.32 (-1.59%) ▼|MS178.47-2.10 (-1.16%) ▼|MSFT533.52+4.47 (+0.84%) ▲|MU904.90+26.06 (+2.97%) ▲|NEE78.17-1.63 (-2.04%) ▼|NFLX69.85-0.68 (-0.96%) ▼|NKE37.21+0.08 (+0.22%) ▲|NOW145.36+3.39 (+2.39%) ▲|NVDA217.09+2.96 (+1.38%) ▲|ORCL129.59+1.36 (+1.06%) ▲|PEP133.57+2.08 (+1.58%) ▲|PFE29.44-0.14 (-0.47%) ▼|PG157.69-1.66 (-1.04%) ▼|PLTR194.15+8.12 (+4.36%) ▲|PM201.05-4.15 (-2.02%) ▼|QCOM173.53+1.42 (+0.83%) ▲|RTX192.11-1.81 (-0.93%) ▼|SBUX97.87+0.35 (+0.36%) ▲|SCHW89.58-2.38 (-2.59%) ▼|SO89.27-1.91 (-2.09%) ▼|SPG202.49-2.95 (-1.44%) ▼|T23.20-0.24 (-1.02%) ▼|TMO679.38-10.62 (-1.54%) ▼|TMUS156.09-3.01 (-1.89%) ▼|TSLA368.06+13.34 (+3.76%) ▲|TXN276.15-0.33 (-0.12%) ▼|UBER69.96-0.39 (-0.55%) ▼|UNH406.88+5.45 (+1.36%) ▲|UNP287.01-2.03 (-0.70%) ▼|UPS97.46-0.02 (-0.02%) ▼|USB57.85-0.88 (-1.50%) ▼|V402.92+0.31 (+0.08%) ▲|VZ44.15-0.64 (-1.43%) ▼|WFC81.80-2.07 (-2.47%) ▼|WMT118.70-0.11 (-0.09%) ▼|XOM178.28-0.70 (-0.39%) ▼|AAPL342.94-0.52 (-0.15%) ▼|ABBV282.68-2.74 (-0.96%) ▼|ABT104.06-0.83 (-0.79%) ▼|ACN236.93+7.25 (+3.16%) ▲|ADBE247.09+1.89 (+0.77%) ▲|AMAT413.11+3.82 (+0.93%) ▲|AMD538.05+9.30 (+1.76%) ▲|AMGN424.94-7.55 (-1.75%) ▼|AMT183.03-2.24 (-1.21%) ▼|AMZN262.45+12.45 (+4.98%) ▲|AVGO334.59+5.84 (+1.78%) ▲|AXP316.41+2.82 (+0.90%) ▲|BA191.42+1.21 (+0.64%) ▲|BAC50.39-0.84 (-1.64%) ▼|BKNG162.60-0.85 (-0.52%) ▼|BLK1,124.60-9.78 (-0.86%) ▼|BMY58.83-0.92 (-1.54%) ▼|BNY142.44-0.86 (-0.60%) ▼|BRK-B532.23+0.21 (+0.04%) ▲|C121.69-2.57 (-2.07%) ▼|CAT725.79-4.97 (-0.68%) ▼|CL93.39-0.72 (-0.77%) ▼|CMCSA21.90+0.00 (+0.00%) ▲|COF199.83-1.91 (-0.95%) ▼|COP145.24-1.27 (-0.87%) ▼|COST995.53+6.42 (+0.65%) ▲|CRM242.45+1.75 (+0.73%) ▲|CSCO106.50-0.89 (-0.83%) ▼|CVS92.68+0.32 (+0.35%) ▲|CVX224.37-0.62 (-0.28%) ▼|DE627.00-14.86 (-2.32%) ▼|DHR224.43-4.61 (-2.01%) ▼|DIS109.59-1.00 (-0.90%) ▼|DUK119.27-2.20 (-1.81%) ▼|EMR160.54-0.93 (-0.58%) ▼|FDX293.78+0.23 (+0.08%) ▲|GD341.43-2.80 (-0.81%) ▼|GE311.28-2.55 (-0.81%) ▼|GEV908.44-12.76 (-1.39%) ▼|GILD153.07-3.12 (-2.00%) ▼|GM82.75-1.21 (-1.44%) ▼|GOOG340.16+3.25 (+0.96%) ▲|GOOGL344.18+3.59 (+1.05%) ▲|GS875.78-5.48 (-0.62%) ▼|HD309.88+0.25 (+0.08%) ▲|HON209.98-1.43 (-0.68%) ▼|IBM236.39+4.25 (+1.83%) ▲|INTC92.03+2.18 (+2.43%) ▲|INTU325.62+0.47 (+0.14%) ▲|ISRG433.18+6.48 (+1.52%) ▲|JNJ253.79-1.77 (-0.69%) ▼|JPM333.53-6.19 (-1.82%) ▼|KO93.42-0.48 (-0.51%) ▼|LIN503.44+5.01 (+1.01%) ▲|LLY1,240.34-16.69 (-1.33%) ▼|LMT548.23-3.86 (-0.70%) ▼|LOW195.92-1.46 (-0.74%) ▼|LRCX272.20+8.26 (+3.13%) ▲|MA616.40-1.02 (-0.17%) ▼|MCD242.67-0.30 (-0.12%) ▼|MDLZ63.34-0.57 (-0.89%) ▼|MDT92.77-1.98 (-2.09%) ▼|META705.44-3.89 (-0.55%) ▼|MMM162.01-2.74 (-1.66%) ▼|MO74.09-1.02 (-1.36%) ▼|MRK143.63-2.32 (-1.59%) ▼|MS178.47-2.10 (-1.16%) ▼|MSFT533.52+4.47 (+0.84%) ▲|MU904.90+26.06 (+2.97%) ▲|NEE78.17-1.63 (-2.04%) ▼|NFLX69.85-0.68 (-0.96%) ▼|NKE37.21+0.08 (+0.22%) ▲|NOW145.36+3.39 (+2.39%) ▲|NVDA217.09+2.96 (+1.38%) ▲|ORCL129.59+1.36 (+1.06%) ▲|PEP133.57+2.08 (+1.58%) ▲|PFE29.44-0.14 (-0.47%) ▼|PG157.69-1.66 (-1.04%) ▼|PLTR194.15+8.12 (+4.36%) ▲|PM201.05-4.15 (-2.02%) ▼|QCOM173.53+1.42 (+0.83%) ▲|RTX192.11-1.81 (-0.93%) ▼|SBUX97.87+0.35 (+0.36%) ▲|SCHW89.58-2.38 (-2.59%) ▼|SO89.27-1.91 (-2.09%) ▼|SPG202.49-2.95 (-1.44%) ▼|T23.20-0.24 (-1.02%) ▼|TMO679.38-10.62 (-1.54%) ▼|TMUS156.09-3.01 (-1.89%) ▼|TSLA368.06+13.34 (+3.76%) ▲|TXN276.15-0.33 (-0.12%) ▼|UBER69.96-0.39 (-0.55%) ▼|UNH406.88+5.45 (+1.36%) ▲|UNP287.01-2.03 (-0.70%) ▼|UPS97.46-0.02 (-0.02%) ▼|USB57.85-0.88 (-1.50%) ▼|V402.92+0.31 (+0.08%) ▲|VZ44.15-0.64 (-1.43%) ▼|WFC81.80-2.07 (-2.47%) ▼|WMT118.70-0.11 (-0.09%) ▼|XOM178.28-0.70 (-0.39%) ▼|
12.2 C
New York
Tuesday, October 20, 2026

Tag: biologics

newssourceFORcompanycontentinformation1releasesmarket

BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsight

The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE),...

BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsight

The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE),...

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the...

CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2 
CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2

Kicking Off Today! Process Intensified. Drug Manufacturing Accelerated. The Sartorius PI Forum opens in Boston — shaping biomanufacturing’s future

Sartorius launches a premier industry event focused on process intensification (PI) for protein therapeutics and emerging modalities.Forum features expert-led sessions, hands-on workshops, and live...

Stewart Investors Identifies Six Global Companies Advancing Health Beyond Pharma

Brown & Brown, Cintas Corporation, Haleon, Linde, Raia Drogasil and Veeva Systems are making access to health and hygiene more equitable. EDINBURGH, Scotland, June...

Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

MINNEAPOLIS, June 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company...

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to...

For media and investors only

IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy...

SHANGHAI and NANJING, China and SAN FRANCISCO, June 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development,...

Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development...

Time Temperature Indicator Market to Reach $1.57 Billion by 2035, Growing at a CAGR of 6.2% from 2025–Exclusive Report by Meticulous Research®

Market Growth Driven by Cold Chain Expansion, IoT Integration, Regulatory Compliance Requirements, and Focus on Food Safety REDDING, Calif., June 20, 2025 /PRNewswire/ -- According to...

Time Temperature Indicator Market to Reach $1.57 Billion by 2035, Growing at a CAGR of 6.2% from 2025–Exclusive Report by Meticulous Research®

Market Growth Driven by Cold Chain Expansion, IoT Integration, Regulatory Compliance Requirements, and Focus on Food Safety REDDING, Calif., June 20, 2025 /PRNewswire/ -- According to...

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

HER2-low Cancers Market Set to Register Immense Growth at a CAGR of 9.4% During the Study Period (2020-2034) | DelveInsight

The future of the HER2-low cancer treatment market is poised for significant transformation, driven by the approval of ENHERTU and the advancement of other...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBiologics

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers